Cancer Headlines PHILADELPHIA , Oct. 28 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved ARRANON(R) (nelarabine) Injection, a chemotherapy agent, for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. Approximately 1,600 adults and children are diagnosed with T-ALL or T-LBL in the U.S. each year. A subset of these patients will relapse or develop disease that is refractory to treatment. There is no standard of treatment for these patients and their prognosis is particularly poor. To facilitate the development of ARRANON for this relatively small group of patients, GSK worked closely with the National Cancer Institute (NCI) of the National Institutes of Health (NIH), the Children's Oncology Group (COG) and the Cancer and Leukemia Group B (CALGB), in conjunction with the Southwest Oncology Group (SWOG).
|
||
|
||
|
||
|
||
|
Lung Cancer Research
Cancer Smart Bomb ResearchDo you remember the Smart Bomb footage of the Gulf Wars on CNN, where the bomb was launched and you watched on full video as the smart munitions flew thru someone’s window and exploded? Well, some really brilliant folks at MIT had an idea. A cancer drug which could go to a cancer cell and penetrate it like a sponge and then seal-a-meal itself in the cancerous region. Then go off and attack the cancerous region without hurting nearby cells. Wow. How did they do it? Using nano-articles, that’s how. The lethal dose of anti-cancer toxins goes off like the Mother of All Bombs and does not hurt the non-cancerous cells. It has been tested on Melanoma and Lewis Lung Cancer in rats so far. Soon clinical trials and tests will begin on real people, but everyone is very excited and pretty certain this will work very well. It was a group effort at MIT, between nano tech, bio-medicine and cancer researchers. They are confident that it will be better for the patient than the chemotherapy due to the reduction of toxicity to the healthy surrounding tissue cells. By using this new research and methodology the MIT team hopes to cur off enemy supply lines, while dropping smart anti-cancer drugs on the cancer cells. Similar to starving out enemy insurgents and then attacking them from the air with precision smart bombs, a strategy which is currently ripping the heart out of our enemy. The nano cell or super Navy Seal like team, is like a balloon within a localized grid of the modern net-centric battlespace. A balloon within a balloon, where it releases the treatment, an anti-angiogenic drug; thus the blood vessels feeding the tumor then collapse, which means the loaded nanoparticles are trapped in the tumor, and release the chemotherapy. It worked in the mice, now it is time to use this to attack cancerous areas in humans. Eighty percent of the mice survived over 65 days; the best so far would have been only 30 days. The untreated mice died at less than 20 days. The nanocell treatment worked best on melanoma than lung cancer, but with a little work the researchers believe they will have an answer for safer treatment for many types of cancers and drastically increase the odds of survival. The future where cancer is conquered is rapidly approaching, that is good news for the World and it means more Lance Armstrong types amongst us. Think on this, because it is all good and it will be here soon. "Lance Winslow" - If you have innovative thoughts and unique perspectives, come think with Lance; www.WorldThinkTank.net/wttbbs Article Source: http://EzineArticles.com/
|
